Anebulo Pharmaceuticals (FRA:214) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Days Payable?

Anebulo Pharmaceuticals's average Accounts Payable for the three months ended in Mar. 2024 was €0.32 Mil. Anebulo Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.00 Mil.

The historical rank and industry rank for Anebulo Pharmaceuticals's Days Payable or its related term are showing as below:

FRA:214's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

Anebulo Pharmaceuticals's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Anebulo Pharmaceuticals Days Payable Historical Data

The historical data trend for Anebulo Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Days Payable Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Days Payable

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Anebulo Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anebulo Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Days Payable falls into.

Anebulo Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Anebulo Pharmaceuticals's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (0.36	+	0.494)	/	2 )	/	0	*	365
=	0.427					/	0	*	365
=	N/A

Anebulo Pharmaceuticals's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0.293	+	0.354)	/	2 )	/	0	*	365 / 4
=	0.3235					/	0	*	365 / 4
=	N/A

Anebulo Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (FRA:214) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ANEB:USA

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals (FRA:214) Headlines

No Headlines